MX2021006730A - Citomegalovirus humano compuesto por antigenos exogenos. - Google Patents
Citomegalovirus humano compuesto por antigenos exogenos.Info
- Publication number
- MX2021006730A MX2021006730A MX2021006730A MX2021006730A MX2021006730A MX 2021006730 A MX2021006730 A MX 2021006730A MX 2021006730 A MX2021006730 A MX 2021006730A MX 2021006730 A MX2021006730 A MX 2021006730A MX 2021006730 A MX2021006730 A MX 2021006730A
- Authority
- MX
- Mexico
- Prior art keywords
- human cytomegalovirus
- exogenous antigens
- vectors
- antigens
- ganciclovir
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 101100315698 Human cytomegalovirus (strain Merlin) UL131A gene Proteins 0.000 abstract 1
- 101150088910 UL82 gene Proteins 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002963 ganciclovir Drugs 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
Abstract
Se describen vectores citomegalovirus humanos que comprenden antígenos heterólogos. Los vectores derivados de la cepa TR, son sensibles a ganciclovir, incluyen genes US2, US3, U6, US7 y UL131A, y tienen una mutación deletérea o inactivante en el gen UL82 que impide la expresión de la pp71.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462025348P | 2014-07-16 | 2014-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006730A true MX2021006730A (es) | 2021-07-15 |
Family
ID=53776978
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000658A MX2017000658A (es) | 2014-07-16 | 2015-07-16 | Citomegalovirus humano compuesto por antígenos exógenos. |
MX2021006730A MX2021006730A (es) | 2014-07-16 | 2017-01-16 | Citomegalovirus humano compuesto por antigenos exogenos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000658A MX2017000658A (es) | 2014-07-16 | 2015-07-16 | Citomegalovirus humano compuesto por antígenos exógenos. |
Country Status (16)
Country | Link |
---|---|
US (3) | US10428118B2 (es) |
EP (2) | EP4194558A1 (es) |
JP (4) | JP6487026B2 (es) |
KR (3) | KR102205348B1 (es) |
CN (2) | CN113528466A (es) |
AP (1) | AP2017009743A0 (es) |
AU (2) | AU2015289560B2 (es) |
BR (1) | BR112017000696B1 (es) |
CA (2) | CA3113595A1 (es) |
EA (1) | EA039174B1 (es) |
IL (1) | IL250130B (es) |
MX (2) | MX2017000658A (es) |
NZ (1) | NZ728208A (es) |
SG (2) | SG11201700315YA (es) |
UA (1) | UA120938C2 (es) |
WO (1) | WO2016011293A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3351636B1 (en) | 2010-05-14 | 2020-07-01 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from a paramyxoviridae virus and uses thereof |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US9783823B2 (en) | 2013-03-05 | 2017-10-10 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
SG11201700315YA (en) | 2014-07-16 | 2017-02-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
EP3256595A4 (en) | 2015-02-10 | 2018-09-26 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
MA43285A (fr) | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
EP3475446A1 (en) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CA3040303A1 (en) * | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
US11617788B2 (en) | 2018-07-09 | 2023-04-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Viral promoters and compositions and methods of use thereof |
GB201906104D0 (en) * | 2019-05-01 | 2019-06-12 | Univ Plymouth | Intrinsic systems for viral vector transgene regulation |
EP4396200A1 (en) * | 2021-08-31 | 2024-07-10 | VIR Biotechnology, Inc. | Methods for producing cmv vectors |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
DE3853139T2 (de) | 1987-06-26 | 1995-06-14 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
EP1092775A1 (en) | 1991-07-05 | 2001-04-18 | American Cyanamid Company | Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
JPH09512177A (ja) | 1994-04-29 | 1997-12-09 | ファルマシア・アンド・アップジョン・カンパニー | ネコ免疫不全ウイルスワクチン |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
AU711121B2 (en) | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
JPH11503024A (ja) | 1995-04-04 | 1999-03-23 | セル・ジェネシス・インコーポレイテッド | 細胞表面のクラスi mhcタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植 |
EP0966301B1 (en) | 1996-07-31 | 2005-02-09 | Ortho-McNeil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
EP1427826B1 (en) | 2001-09-20 | 2011-04-20 | Glaxo Group Limited | HIV- RT-nef-Gag codon optimised DNA vaccines |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
EP1497412A4 (en) | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS FOR IMMUNOTHERAPY |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
WO2005012545A2 (en) | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
US20080044384A1 (en) | 2004-06-25 | 2008-02-21 | Medlmmune Vaccines, Inc. | Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens |
WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
SI2215117T2 (en) | 2007-10-30 | 2018-04-30 | Genentech, Inc. | Purification of the antibody by cation exchange chromatography |
JP2012519484A (ja) | 2009-03-06 | 2012-08-30 | マウント・シナイ・スクール・オヴ・メディシン | マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン |
SG181901A1 (en) | 2009-12-23 | 2012-08-30 | 4Antibody Ag | Binding members for human cytomegalovirus |
US20120289760A1 (en) | 2010-01-27 | 2012-11-15 | Hill Ann B | Cytomegalovirus-based immunogenic preparations |
JP2011177071A (ja) * | 2010-02-26 | 2011-09-15 | Aichi Prefecture | 弱毒hcmv及びそのワクチンとしての使用 |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
SG10201503450WA (en) | 2010-05-05 | 2015-06-29 | Thirion Christian | Vaccine against beta-herpesvirus infection and use thereof |
EP3351636B1 (en) | 2010-05-14 | 2020-07-01 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from a paramyxoviridae virus and uses thereof |
CA2832109C (en) * | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
TWI570240B (zh) | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製cmv |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
ES2608637T3 (es) * | 2012-10-30 | 2017-04-12 | Pfizer Inc. | Vacunas basadas en partículas recombinantes contra la infección por el citomegalovirus humano |
US9783823B2 (en) | 2013-03-05 | 2017-10-10 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
SG11201700315YA (en) | 2014-07-16 | 2017-02-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
EP3256595A4 (en) | 2015-02-10 | 2018-09-26 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
MA43285A (fr) | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2015
- 2015-07-16 SG SG11201700315YA patent/SG11201700315YA/en unknown
- 2015-07-16 EA EA201790167A patent/EA039174B1/ru unknown
- 2015-07-16 MX MX2017000658A patent/MX2017000658A/es unknown
- 2015-07-16 KR KR1020197018702A patent/KR102205348B1/ko active IP Right Grant
- 2015-07-16 UA UAA201701206A patent/UA120938C2/uk unknown
- 2015-07-16 WO PCT/US2015/040807 patent/WO2016011293A1/en active Application Filing
- 2015-07-16 KR KR1020177004156A patent/KR101996427B1/ko active IP Right Grant
- 2015-07-16 EP EP22209713.1A patent/EP4194558A1/en active Pending
- 2015-07-16 SG SG10201907249WA patent/SG10201907249WA/en unknown
- 2015-07-16 CN CN202110650460.9A patent/CN113528466A/zh active Pending
- 2015-07-16 CN CN201580045987.1A patent/CN107002048B/zh active Active
- 2015-07-16 BR BR112017000696-0A patent/BR112017000696B1/pt active IP Right Grant
- 2015-07-16 US US15/326,444 patent/US10428118B2/en active Active
- 2015-07-16 CA CA3113595A patent/CA3113595A1/en active Pending
- 2015-07-16 KR KR1020217001036A patent/KR102403547B1/ko active IP Right Grant
- 2015-07-16 JP JP2017502666A patent/JP6487026B2/ja active Active
- 2015-07-16 AP AP2017009743A patent/AP2017009743A0/en unknown
- 2015-07-16 EP EP15745663.3A patent/EP3169787A1/en not_active Withdrawn
- 2015-07-16 NZ NZ728208A patent/NZ728208A/en unknown
- 2015-07-16 CA CA2955306A patent/CA2955306C/en active Active
- 2015-07-16 AU AU2015289560A patent/AU2015289560B2/en active Active
-
2017
- 2017-01-15 IL IL250130A patent/IL250130B/en active IP Right Grant
- 2017-01-16 MX MX2021006730A patent/MX2021006730A/es unknown
-
2018
- 2018-11-26 AU AU2018267687A patent/AU2018267687B2/en active Active
-
2019
- 2019-02-19 JP JP2019027030A patent/JP6925376B2/ja active Active
- 2019-08-20 US US16/545,561 patent/US10995121B2/en active Active
-
2021
- 2021-03-26 US US17/214,598 patent/US11692012B2/en active Active
- 2021-08-03 JP JP2021127653A patent/JP7299275B2/ja active Active
-
2023
- 2023-06-15 JP JP2023098250A patent/JP2023116706A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006730A (es) | Citomegalovirus humano compuesto por antigenos exogenos. | |
MX2023003246A (es) | Metodos y composiciones para atenuar las respuestas inmunes anti-vector de transferencia viral que modula la expresion de genes. | |
MX2018005084A (es) | Genes de ataxia de friedreich modificados y vectores para terapia genica. | |
MX2018005286A (es) | Constructo genetico. | |
MX2023004479A (es) | Sistema de vector multiple y sus usos. | |
ZA201606763B (en) | Aav vectors for retinal and cns gene therapy | |
EP3222728A4 (en) | Method for regulating gene expression using cas9 protein expressed from two vectors | |
SA517380883B1 (ar) | Viii مجموعة تعبير متطورة لحزم والتعبير عن عامل متغير لعلاج اضطراب توقف نزيف الدم | |
MX2017016400A (es) | Vectores para uso en un sistema de coexpresion inducible. | |
MX2018001055A (es) | Promotores para mejorar la expresion en poxvirus. | |
MX2020003385A (es) | Vectores adenovirales de replicacion competente. | |
IL279281A (en) | Optimizing BAG3 gene therapy | |
IL280165A (en) | Glucocerebrosidase gene therapy | |
MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
MX2017004769A (es) | Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas. | |
GB2572716B (en) | Gene Therapy Vector System and Prodrug Genes | |
EP3847259A4 (en) | VTVAF17 VECTOR-BASED GENE THERAPY | |
MX2019006551A (es) | Terapia génica para mucopolisacaridosis de tipo ii. | |
TH1701000216A (th) | ไซโตเมกาโลไวรัสมนุษย์ที่ประกอบรวมด้วยแอนติเจนจากภายนอก | |
MX2020008779A (es) | Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exogenos y vacunas elaboradas a partir de estos. | |
GB201811540D0 (en) | Gaucher gene therapy |